BRIEF-GSK, Theravance say positive FF/VI phase III study to support filing in Japan

April 22 Tue Apr 22, 2014 8:42am EDT

April 22 (Reuters) -

* GSK & Theravance announce phase III study of FF/VI in COPD commenced to support potential future filing in Japan

* Positive results from this study will help support a potential filing of FF/VI for treatment of patients with COPD in Japan.

* Study will evaluate contribution of ICS component on lung function, in patients with chronic obstructive pulmonary disease (COPD)

* GSK chose to withdraw COPD file in Japan while designing an additional study

Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.